Share on StockTwits

CryoLife (NYSE:CRY) VP Jeffrey W. Burris unloaded 11,000 shares of the company’s stock on the open market in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $10.50, for a total transaction of $115,500.00. Following the completion of the transaction, the vice president now directly owns 93,576 shares in the company, valued at approximately $982,548. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of CryoLife (NYSE:CRY) traded down 1.33% during mid-day trading on Thursday, hitting $10.35. 59,842 shares of the company’s stock traded hands. CryoLife has a 52-week low of $6.01 and a 52-week high of $12.14. The stock’s 50-day moving average is $9.48 and its 200-day moving average is $9.50. The company has a market cap of $289.0 million and a price-to-earnings ratio of 19.57.

CryoLife (NYSE:CRY) last issued its quarterly earnings data on Thursday, July 24th. The company reported $0.08 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.05 by $0.03. The company had revenue of $34.69 million for the quarter, compared to the consensus estimate of $35.72 million. During the same quarter in the prior year, the company posted $0.08 earnings per share. The company’s quarterly revenue was up 3.6% on a year-over-year basis. On average, analysts predict that CryoLife will post $0.20 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which is scheduled for Friday, September 19th. Shareholders of record on Friday, September 12th will be paid a dividend of $0.03 per share. This represents a $0.12 annualized dividend and a dividend yield of 1.14%. The ex-dividend date is Wednesday, September 10th.

CryoLife, Inc (NYSE:CRY) is a biological medical device company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.